Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

Shares of Eli Lilly LLY soared 14.3% on April 17 ... Novo Nordisk markets its semaglutide drugs as Ozempic for T2D and Wegovy for weight management. NVO also markets Rybelsus as an oral medication ...

Shares of Eli Lilly LLY soared 14.3% on April 17 after data from a late-stage study showed that orforglipron achieved the ...

GLP-1 medicines can be helpful tools for the treatment of obesity and for other important health goals, but they’re not for ...

After 40 weeks of treatment in the multi-dose trial, orforglipron showed body weight reductions of 4.7% at 3 mg, 6.1% with 12 mg ... Nordisk had already introduced the first oral semaglutide called ...

Novo Nordisk filed for approval of an oral, 25-mg formulation of its weight loss blockbuster “earlier this year,” according ...

A spokesperson confirmed the Danish drugmaker has asked U.S. regulators to clear an oral version of its weight loss drug ...

But the oral form of semaglutide, marketed as Rybelsus, has a much thinner body of evidence behind it. While the medication does work, its benefits are more modest than its injectable counterparts.

For example, spending for Ozempic increased from $0.4 billion to $26.4 billion, but combined spending on Victoza, Bydureon and Byetta decreased by $4 billion from $7.1 billion to $3.1 billion.